Suppr超能文献

医院获得性鲍曼不动杆菌感染和不断变化的抗生素耐药性。

Nosocomial Acinetobacter baumannii Infections and Changing Antibiotic Resistance.

机构信息

Ismail Necati Hakyemez, Specialist of Infectious Diseases and Clinical Microbiology, Sevket Yilmaz Training and Research Hospital, Bursa, Turkey.

Abdulkadir Kucukbayrak, Assistant Professor of Infectious Diseases and Clinical Microbiology, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey.

出版信息

Pak J Med Sci. 2013 Sep;29(5):1245-8. doi: 10.12669/pjms.295.3885.

Abstract

OBJECTIVES

In the intensive care setting, Acinetobacter baumannii causes ventilator-associated pneumonia and other nosocomial infections that are difficult to treat. Objective of this study was to investigate nosocomial A. baumannii infections and its changing antibiotic resistance.

METHODS

A total of 56 patients diagnosed with A.baumannii infections between January 2009 and December 2011 were included in the study. Diagnosis for nosocomial infections was established according to the CDC (Centers for Disease Control and Prevention) criteria. Identification of the agents isolated was carried out using conventional methods and VITEK 2 automated system, while antibiotic sensitivity testing was performed through VITEK 2 AST-N090 automated system.

RESULTS

The most common infection was nosocomial pneumonia by 43%, among which 46% were ventilator-associated pneumonia. Considering all years, the most effective antibiotics on the isolated strains were found as colistin, tigecycline, imipenem and meropenem. However resistance to imipenem and meropenem was observed to increase over years.

CONCLUSION

The issue of increased resistance to antibiotics poses difficulty in treatment of A. baumannii infections which in turn increases the rate of mortality and cost. In order to prevent development of resistance, antibiotics must be used in an appropriate way in accompanied with proper guidance.

摘要

目的

在重症监护病房,鲍曼不动杆菌可引起呼吸机相关性肺炎和其他医院感染,这些感染难以治疗。本研究的目的是调查医院获得性鲍曼不动杆菌感染及其抗生素耐药性的变化。

方法

本研究共纳入 2009 年 1 月至 2011 年 12 月期间诊断为鲍曼不动杆菌感染的 56 例患者。医院感染的诊断根据美国疾病控制与预防中心(CDC)的标准确定。采用常规方法和 VITEK 2 自动化系统进行分离物的鉴定,采用 VITEK 2 AST-N090 自动化系统进行抗生素敏感性检测。

结果

最常见的感染是医院获得性肺炎,占 43%,其中 46%为呼吸机相关性肺炎。考虑所有年份,分离株最有效的抗生素为黏菌素、替加环素、亚胺培南和美罗培南。然而,亚胺培南和美罗培南的耐药性呈逐年上升趋势。

结论

抗生素耐药性增加的问题给鲍曼不动杆菌感染的治疗带来了困难,从而增加了死亡率和成本。为了防止耐药性的发展,抗生素的使用必须与适当的指导相结合,以适当的方式使用。

相似文献

1
Nosocomial Acinetobacter baumannii Infections and Changing Antibiotic Resistance.
Pak J Med Sci. 2013 Sep;29(5):1245-8. doi: 10.12669/pjms.295.3885.
2
A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital.
Infect Chemother. 2016 Sep;48(3):190-198. doi: 10.3947/ic.2016.48.3.190. Epub 2016 Sep 9.
8
Acinetobacter baumannii nosocomial infections.
Pol Przegl Chir. 2013 Sep;85(9):483-90. doi: 10.2478/pjs-2013-0075.

引用本文的文献

1
Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis.
PLoS One. 2024 Dec 16;19(12):e0311124. doi: 10.1371/journal.pone.0311124. eCollection 2024.
2
β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward.
Front Microbiol. 2023 Mar 10;13:1092556. doi: 10.3389/fmicb.2022.1092556. eCollection 2022.
3
Detection of the and aac (3)-1V resistance genes in .
Arch Razi Inst. 2022 Jun 30;77(3):959-966. doi: 10.22092/ari.2022.357271.2010. eCollection 2022 Jun.
4
Characterization and Inhibition of 1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase: A Promising Drug Target in and .
ACS Infect Dis. 2021 Nov 12;7(11):2987-2998. doi: 10.1021/acsinfecdis.1c00132. Epub 2021 Oct 21.
5
Mechanical ventilation enhances Acinetobacter baumannii-induced lung injury through JNK pathways.
Respir Res. 2021 May 22;22(1):159. doi: 10.1186/s12931-021-01739-3.
6
Pan drug-resistant causing nosocomial infections among burnt children.
Med J Islam Repub Iran. 2020 Mar 23;34:24. doi: 10.34171/mjiri.34.24. eCollection 2020.
7
Resistance: A Real Challenge for Clinicians.
Antibiotics (Basel). 2020 Apr 23;9(4):205. doi: 10.3390/antibiotics9040205.
8
Antibiotic resistance in patients suffering from nosocomial infections in Besat Hospital.
Eur J Transl Myol. 2018 Jul 16;28(3):7594. doi: 10.4081/ejtm.2018.7594. eCollection 2018 Jul 10.
10
Spread of carbapenem-resistant international clones of Acinetobacter baumannii in Turkey and Azerbaijan: a collaborative study.
Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1463-8. doi: 10.1007/s10096-016-2685-x. Epub 2016 Jun 4.

本文引用的文献

1
Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis.
Braz J Infect Dis. 2013 Jul-Aug;17(4):389-94. doi: 10.1016/j.bjid.2012.10.029. Epub 2013 Apr 19.
2
Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.
Expert Rev Anti Infect Ther. 2013 Apr;11(4):383-93. doi: 10.1586/eri.13.14.
3
Analysis of carbapenem-resistant Acinetobacter from a tertiary care setting in North India.
Indian J Med Microbiol. 2013 Jan-Mar;31(1):60-3. doi: 10.4103/0255-0857.108724.
6
OXA-type carbapenemases in Acinetobacter baumannii in South America.
J Infect Dev Ctries. 2012 Apr 13;6(4):311-6. doi: 10.3855/jidc.2310.
8
Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
J Antimicrob Chemother. 2012 Jul;67(7):1607-15. doi: 10.1093/jac/dks084. Epub 2012 Mar 22.
9
Colistin: new lessons on an old antibiotic.
Clin Microbiol Infect. 2012 Jan;18(1):18-29. doi: 10.1111/j.1469-0691.2011.03734.x.
10
Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options.
Int J Antimicrob Agents. 2012 Feb;39(2):105-14. doi: 10.1016/j.ijantimicag.2011.10.004. Epub 2011 Nov 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验